Bio-Techne (TECH) concentration risks

The company's disclosed concentration profile is shaped by a single product-segment exposure: the Protein Sciences segment, the larger of the two reported segments, represented approximately 72% of net sales in fiscal 2025. This is a high-share, structural concentration reflecting the company's primary area of scientific and commercial focus. The structural character means the exposure is embedded in the business model — the segment's leadership position in protein research reagents and tools is what defines the company's market identity — rather than reflecting reliance on a specific customer or contract that could be abruptly terminated. Because the filing discloses only this single concentration exposure, the profile is narrow in scope but significant in scale. A high share of revenue flowing from one business segment means that disruptions specific to protein sciences demand — whether from shifts in academic and biopharmaceutical research funding, competitive displacement by alternative technologies, or a slowdown in biopharma R&D spending — would flow through to consolidated results with limited natural offset from the smaller segment. At the same time, the structural character of the exposure argues for durability: the Protein Sciences segment occupies a well-established role in the life sciences supply chain, and demand for its products tends to be driven by long-cycle research activity rather than short-term procurement decisions. There is no disclosed customer, geographic, or supplier concentration on top of this segment tilt, which means the primary risk is sector-level life sciences research spending rather than any single counterparty dependency.

For the engine’s reasoning on TECH’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.